Pharmaceutical Intermediate CAS 402957-28-2 Telaprevir Vx-950 Telaprevir Intermediate Raw Material Telaprevir

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Telaprevir
• Product Name: Telaprevir
• Name: Telaprevir Powder
• Appearance: off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 402957-28-2
• Mf: C36h53n7o6
• MW: 679.863
• Density: 1.25
• Melting Point: 221-224 C
• Refractive Index: 1.584
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical Intermediate CAS 402957-28-2 Telaprevir VX-950 Telaprevir Intermediate Raw Material Telaprevir

 

Product Description

Product Details

Product Name	Telaprevir
CAS No.	402957-28-2
MF	C36h53n7o6
MW	679.863
Appearance and shape	off-White Powder

Telaprevir is a peptidomimetic inhibitor of hepatitis C virus protease.
Physicians prescribe the antiviral medication telaprevir in conjunction with peginterferon alfa and ribavirin for the treatment of the hepatitis C virus (HCV).  The HCV drug not only increases the likelihood of disabling the virus but also may decrease the amount of time patients require treatment.  The treatment regimen may cause anemia and typically produces flu-like symptoms.  Telaprevir interacts with many prescribed medications.
Telaprevir is a protease inhibitor antiviral medication that interferes with the NS3/4A serine protease.  This enzyme is responsible for protein maturity and protein adhesion.  When these processes are inhibited, the virus cannot replicate.  Genotype 1 hepatitis C virus is the most common strain of the disease and is also most resistant to treatment.  Treating HCV does not completely eliminate the virus from the body.  The medications, however, usually decrease the viral load to the point where the infection becomes undetectable.

Application & Function

A labelled peptidomimetic inhibitor of hepatitis C virus protease.
Conventional therapy typically involved a combination regimen of peginterferon alfa and ribavirin taken for 24 to 48 weeks. Some patients experience difficulty adhering to the treatment as prescribed because of the length of therapy. Other patients discontinue therapy because of the side effects associated with the medications. Of the individuals adhering to the prescribed therapy, up to one half experienced a resurgence of the virus.

Specification